| 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 |
---|
Net income (loss) | 117 | -234 | 51 |
---|
Depreciation | 64 | 64 | 77 |
---|
Amortization of intangible assets | 87 | 82 | 81 |
---|
Impairment of investment in unconsolidated affiliate | - | 10 | - |
---|
Loss on extinguishment of debt | -21 | - | - |
---|
Deferred income taxes | -4 | -74 | 3 |
---|
Share-based compensation expense | 14 | 21 | 32 |
---|
Accretion expense | 2 | 2 | 2 |
---|
Unrealized foreign exchange loss (gain) | -1 | 4 | -6 |
---|
Unrealized loss (gain) on derivatives not designated as hedging instruments | - | -3 | 2 |
---|
Amortization of debt issuance costs | 6 | 6 | 9 |
---|
Other | 13 | 7 | 5 |
---|
Accounts receivable | 16 | 13 | 22 |
---|
Inventories | 20 | -14 | 10 |
---|
Other current assets | 4 | 6 | -4 |
---|
Accounts payable | 20 | 1 | -5 |
---|
Accrued liabilities | 2 | 21 | 4 |
---|
Litigation settlement | - | - | -35 |
---|
Illinois EO litigation settlement | - | - | 408 |
---|
Georgia EO litigation settlement | - | - | -35 |
---|
Income taxes payable / receivable, net | 10 | -12 | 1 |
---|
Other liabilities | -0 | 0 | -2 |
---|
Other long-term assets | 4 | 5 | 0 |
---|
Net cash provided by (used in) operating activities | 282 | 278 | -148 |
---|
Net income (loss) | 117 | -234 | 51 |
---|
Depreciation | 64 | 64 | 77 |
---|
Amortization of intangible assets | 87 | 82 | 81 |
---|
Impairment of investment in unconsolidated affiliate | - | 10 | - |
---|
Loss on extinguishment of debt | -21 | - | - |
---|
Deferred income taxes | -4 | -74 | 3 |
---|
Share-based compensation expense | 14 | 21 | 32 |
---|
Accretion expense | 2 | 2 | 2 |
---|
Unrealized foreign exchange loss (gain) | -1 | 4 | -6 |
---|
Unrealized loss (gain) on derivatives not designated as hedging instruments | - | -3 | 2 |
---|
Amortization of debt issuance costs | 6 | 6 | 9 |
---|
Other | 13 | 7 | 5 |
---|
Accounts receivable | 16 | 13 | 22 |
---|
Inventories | 20 | -14 | 10 |
---|
Other current assets | 4 | 6 | -4 |
---|
Accounts payable | 20 | 1 | -5 |
---|
Accrued liabilities | 2 | 21 | 4 |
---|
Litigation settlement | - | - | -35 |
---|
Illinois EO litigation settlement | - | - | 408 |
---|
Georgia EO litigation settlement | - | - | -35 |
---|
Income taxes payable / receivable, net | 10 | -12 | 1 |
---|
Other liabilities | -0 | 0 | -2 |
---|
Other long-term assets | 4 | 5 | 0 |
---|
Net cash provided by (used in) operating activities | 282 | 278 | -148 |
---|
Purchases of property, plant and equipment | 102 | 182 | 215 |
---|
Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
---|
Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
---|
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
---|
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
---|
Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
---|
Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
---|
Other investing activities | 1 | -0 | -0 |
---|
Other investing activities | 1 | -0 | -0 |
---|
Net cash used in investing activities | -160 | -182 | -215 |
---|
Net cash used in investing activities | -160 | -182 | -215 |
---|
Proceeds from Issuance of Long-Term Debt | - | 200 | 500 |
---|
Payment of revolving credit facility | - | - | 200 |
---|
Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
---|
Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
---|
Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
---|
Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
---|
Payments of long-term borrowings | 100 | - | 3 |
---|
Payments of long-term borrowings | 100 | - | 3 |
---|
Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
---|
Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
---|
Other financing activities | -1 | -2 | -2 |
---|
Other financing activities | -1 | -2 | -2 |
---|
Net cash provided by (used in) financing activities | -117 | 198 | 266 |
---|
Net cash provided by (used in) financing activities | -117 | 198 | 266 |
---|
Effect of exchange rate changes on cash and cash equivalents | 0 | -4 | 2 |
---|
Net increase (decrease) in cash and cash equivalents, including restricted cash | 4 | 289 | -95 |
---|
Cash paid during the period for interest | 59 | 76 | 174 |
---|
Income Taxes Paid, Net | 52 | 75 | 50 |
---|
Capital Expenditures Incurred but Not yet Paid | 15 | 16 | 17 |
---|
Purchases of property, plant and equipment | 102 | 182 | 215 |
---|
Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
---|
Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
---|
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
---|
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
---|
Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
---|
Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
---|
Other investing activities | 1 | -0 | -0 |
---|
Other investing activities | 1 | -0 | -0 |
---|
Net cash used in investing activities | -160 | -182 | -215 |
---|
Net cash used in investing activities | -160 | -182 | -215 |
---|
Proceeds from Issuance of Long-Term Debt | - | 200 | 500 |
---|
Payment of revolving credit facility | - | - | 200 |
---|
Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
---|
Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
---|
Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
---|
Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
---|
Payments of long-term borrowings | 100 | - | 3 |
---|
Payments of long-term borrowings | 100 | - | 3 |
---|
Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
---|
Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
---|
Other financing activities | -1 | -2 | -2 |
---|
Other financing activities | -1 | -2 | -2 |
---|
Net cash provided by (used in) financing activities | -117 | 198 | 266 |
---|
Net cash provided by (used in) financing activities | -117 | 198 | 266 |
---|
Effect of exchange rate changes on cash and cash equivalents | 0 | -4 | 2 |
---|
Net increase (decrease) in cash and cash equivalents, including restricted cash | 4 | 289 | -95 |
---|
Cash paid during the period for interest | 59 | 76 | 174 |
---|
Income Taxes Paid, Net | 52 | 75 | 50 |
---|
Capital Expenditures Incurred but Not yet Paid | 15 | 16 | 17 |
---|